We are live on ! Find out more
NTUS

Natus Medical Inc

Delisted

NTUS was delisted on the 20th of July, 2022.

133 hedge funds and large institutions have $372M invested in Natus Medical Inc in 2013 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 46 increasing their positions, 44 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

77% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 13

13% more capital invested

Capital invested by funds: $329M → $372M (+$42.3M)

7% more funds holding

Funds holding: 124133 (+9)

5% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 44

97% less call options, than puts

Call options by funds: $16K | Put options by funds: $512K

Holders
133
Holders Change
+9
Holders Change %
+7.26%
% of All Funds
4.31%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.06%
New
23
Increased
46
Reduced
44
Closed
13
Calls
$16K
Puts
$512K
Net Calls
-$496K
Net Calls Change
-$122K
Name Holding Trade Value Shares
Change
Change in
Stake
BC
1
Broadfin Capital
New York
$35.7M -$936K -70,000 -3%
BFA
2
BlackRock Fund Advisors
California
$25.8M +$1.55M +115,557 +7%
Wellington Management Group
3
Wellington Management Group
Massachusetts
$20.6M +$18.4M +1,378,644 +1,869%
EAM
4
Eagle Asset Management
Florida
$18.9M +$2.26M +168,931 +14%
Dimensional Fund Advisors
5
Dimensional Fund Advisors
Texas
$18.6M +$1.1M +82,018 +7%
Bank of New York Mellon
6
Bank of New York Mellon
New York
$17.7M -$7.04M -526,475 -30%
CCM
7
Corsair Capital Management
New York
$15.7M +$405K +30,266 +3%
Vanguard Group
8
Vanguard Group
Pennsylvania
$15.3M +$204K +15,234 +1%
Diamond Hill Capital Management
9
Diamond Hill Capital Management
Ohio
$14.3M +$12.6M +940,250 +1,413%
BIT
10
BlackRock Institutional Trust
California
$14M -$519K -38,846 -4%
KCM
11
Kennedy Capital Management
Missouri
$9.65M +$157K +11,743 +2%
TAM
12
THB Asset Management
Connecticut
$8.52M -$140K -10,500 -2%
Fidelity Investments
13
Fidelity Investments
Massachusetts
$8.51M -$1K -75 -0%
State Street
14
State Street
Massachusetts
$8.47M +$80K +5,985 +1%
TCM
15
Tamarack Capital Management
California
$8.35M +$5.86M +437,936 +290%
CPIM
16
Columbia Partners Investment Management
Virginia
$8.31M -$925K -69,186 -11%
RCMC
17
RK Capital Management (Colorado)
Colorado
$7.67M +$7.23M +540,696 New
Northern Trust
18
Northern Trust
Illinois
$7.19M +$250K +18,676 +4%
Boston Partners
19
Boston Partners
Massachusetts
$6.64M +$5.84M +436,530 +1,364%
MFAM
20
Motley Fool Asset Management
Virginia
$6.19M
BCM
21
Beddow Capital Management
Wyoming
$5.96M +$140K +10,500 +3%
PCM
22
Penn Capital Management
Pennsylvania
$4.96M +$561K +41,970 +14%
RFC
23
Russell Frank Company
Washington
$4.53M +$365K +27,306 +9%
Norges Bank
24
Norges Bank
Norway
$3.97M
TC
25
TFS Capital
Pennsylvania
$3.4M +$681K +50,942 +27%

NTUS Hedge Fund Activity: Q3 2013 in Review

133 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Natus Medical Inc (NTUS) for Q3 2013, worth a combined $372M — up 13% from $329M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new NTUS positions and 13 closed out — a net gain of 10 holders — while 46 added to existing stakes and 44 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $18.4M. The largest seller was OrbiMed, exiting entirely with an estimated $19.5M sold.

  • 133 institutional investors held Natus Medical Inc (NTUS) as of Q3 2013, up from 124 in Q2 2013.
  • Funds reported $372M of Natus Medical Inc stock for Q3 2013, up 13% quarter-over-quarter.
  • 23 funds opened new Natus Medical Inc positions in Q3 2013 and 13 closed out, a net change of +10 holders.
  • The largest Natus Medical Inc buyer in Q3 2013 was Wellington Management Group, an estimated $18.4M added.
  • The largest Natus Medical Inc seller in Q3 2013 was OrbiMed, an estimated $19.5M sold.

Based on aggregated 13F filings for Q3 2013.